CRISPR Therapeutics

CRSP | NASDAQ | 29 Followers

$36.31

1.99%

$36.31

Overview Metrics Financials

Fair Price

$60.96

Undervalued by 64.6%

To display the fair price of a share, you need to be a member of Bulios Black.

Company Quality

Profitability Score

0/100

Solvency Score

52/100

Dividends

Dividends data currently unavailable.

Earnings

8/4/2025

in 80 days

Revenue est.

EPS est.

My Notes

You haven't added any notes for this stock yet. Use this space to record your insights or strategies.

Profile

Healthcare

Sector

Biotechnology

Industry

Dr. Samarth Kulkarni Ph.D.

CEO

393

Employees

Zug

Headquarters

Country

CRISPR Therapeutics AG is a Swiss biotechnology company specializing in the development of therapeutics based on the revolutionary CRISPR-Cas9 technology. This technology enables precise and efficient editing of genetic material, opening up new possibilities in treating genetic diseases and other conditions. CRISPR Therapeutics focuses its research on the treatment of various genetic disorders, including beta-thalassemia and muscular dystrophy. The company collaborates with renowned scientific institutions and experts to strengthen its research and develop new therapeutic approaches. CRISPR Therapeutics AG is an innovative player in the biotechnology industry and is committed to bringing revolutionary treatments to patients with genetic diseases. CRISPR Therapeutics AG (CRSP) shares represent an attractive investment opportunity for investors who follow the biotechnology sector and seek an innovative company engaged in treating genetic disorders.

CRISPR Therapeutics

Fair Price

Company Quality

Dividends

Earnings

My Notes

Profile

Key Metrics TTM

Performance

Earnings Waterfall

Debt level and coverage

Earnings

Feed

Log in to Bulios

Create Bulios profile

Why Bulios?